Cargando…

Three Prognostic Biomarkers Correlate with Immune Checkpoint Blockade Response in Bladder Urothelial Carcinoma

AIM: We aim to develop a signature that could accurately predict prognosis and evaluate the response to immune checkpoint blockade (ICB) in bladder urothelial carcinoma (BLCA). METHODS: Based on comprehensive analysis of public database, we identified prognosis-related hub genes and investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Ya, Zhang, Yin Bin, Li, Yi, Su, Wang Hui, He, Shan, Pan, Shu Pei, Xu, Kun, Kou, Wei Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162857/ https://www.ncbi.nlm.nih.gov/pubmed/35664691 http://dx.doi.org/10.1155/2022/3342666

Ejemplares similares

Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy
por: Cheng, Wen, et al.
Publicado: (2018)

Analysis of prognostic oncogene filaggrin (FLG) wild-type subtype and its implications for immune checkpoint blockade therapy in bladder urothelial carcinoma
por: Chen, Liang, et al.
Publicado: (2022)

KDELR2 as a diagnostic and prognostic biomarker of bladder urothelial carcinoma and its correlation with immune infiltration
por: Ma, Sai, et al.
Publicado: (2023)

PRR11 is a prognostic biomarker and correlates with immune infiltrates in bladder urothelial carcinoma
por: Ni, Wenpeng, et al.
Publicado: (2023)

Predictive biomarkers for tumor immune checkpoint blockade
por: Tong, Mengting, et al.
Publicado: (2018)

RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer
por: Manzano, Ramon Gonzalez, et al.
Publicado: (2021)

Immune checkpoint blockade therapy for bladder cancer treatment
por: Kim, Jayoung
Publicado: (2016)

The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer
por: Xu, Yufei, et al.
Publicado: (2022)

Urothelial Bladder Cancer Urinary Biomarkers
por: Noon, Aidan P, et al.
Publicado: (2014)

Combination Biomarker of Immune Checkpoints Predict Prognosis of Urothelial Carcinoma
por: Tsai, Chung-Ying, et al.
Publicado: (2021)

Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study
por: Ruiz-Bañobre, J., et al.
Publicado: (2021)

Molecular T-Cell Repertoire Analysis as Source of Prognostic and Predictive Biomarkers for Checkpoint Blockade Immunotherapy
por: Aversa, Ilenia, et al.
Publicado: (2020)

Transcriptome sequencing identifies ANLN as a promising prognostic biomarker in bladder urothelial carcinoma
por: Zeng, Shuxiong, et al.
Publicado: (2017)

Tropomyosins: Potential Biomarkers for Urothelial Bladder Cancer
por: Humayun-Zakaria, Nada, et al.
Publicado: (2019)

Clinicopathological and prognostic significance of Ephrin A3 in bladder urothelial carcinoma
por: Wang, Yi-Fan, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives
por: Roviello, Giandomenico, et al.
Publicado: (2021)

PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
por: Tan, Kien Thiam, et al.
Publicado: (2020)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer
por: Parent, Pauline, et al.
Publicado: (2023)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
Publicado: (2021)

Independent prognostic miRNAs for bladder urothelial carcinoma
por: Hu, Yingbo, et al.
Publicado: (2017)

Identification of Prognostic Immune Genes in Bladder Urothelial Carcinoma
por: Su, Qisheng, et al.
Publicado: (2020)

A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer
por: D’Costa, Jamie J., et al.
Publicado: (2016)

Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
por: Peranzoni, Elisa, et al.
Publicado: (2020)

Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
por: Xiao, Qingyang, et al.
Publicado: (2020)

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
por: Lei, Yanna, et al.
Publicado: (2021)

Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade
por: Lavoie, Jean-Michel, et al.
Publicado: (2022)

Metabolomic adaptations and correlates of survival to immune checkpoint blockade
por: Li, Haoxin, et al.
Publicado: (2019)

Identification of a Novel Tumor Microenvironment Prognostic Signature for Bladder Urothelial Carcinoma
por: Xu, Chaojie, et al.
Publicado: (2022)

Bladder-Sparing Chemoradiotherapy Combined with Immune Checkpoint Inhibition for Locally Advanced Urothelial Bladder Cancer—A Review
por: van Hattum, Jons W., et al.
Publicado: (2021)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
Publicado: (2020)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
por: Tu, Megan M., et al.
Publicado: (2019)

Pancancer Analysis of Neurovascular-Related NRP Family Genes as Potential Prognostic Biomarkers of Bladder Urothelial Carcinoma
por: Deng, Chao, et al.
Publicado: (2021)

Epigenetic inactivation of DNA repair genes as promising prognostic and predictive biomarkers in urothelial bladder carcinoma patients
por: Mohanad, Marwa, et al.
Publicado: (2022)

Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer
por: Khan, Zia, et al.
Publicado: (2020)

Clinical, demographic and histopathological prognostic factors for urothelial carcinoma of the bladder
por: Kucuk, Ulku, et al.
Publicado: (2015)

TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle
por: Jiang, Yi, et al.
Publicado: (2023)

Microbial biomarkers for immune checkpoint blockade therapy against cancer
por: Adachi, Keishi, et al.
Publicado: (2018)

Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
por: Shen, Hongxing, et al.
Publicado: (2019)

A Comprehensive Benchmark of Transcriptomic Biomarkers for Immune Checkpoint Blockades
por: Kang, Hongen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1e3nmhp3naf5p66q57vi0dj1r1